Skip to content

Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India

Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07290972
Acronym
NCG-Compliance
Enrollment
618
Registered
2025-12-18
Start date
2021-02-01
Completion date
2026-03-31
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer Screening, Chemoradiotherapy, Gynecologic Cancers, Treatment Compliance

Keywords

Cervical cancer, Cancer, Recurrence, Treatment, Compliance, Chemoradiotherapy

Brief summary

This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+/- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and/or concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included. As a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing. Each of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted. Those centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and /or concurrent chemotherapy over a period of 6 months.

Detailed description

Investigator intend to use electronic case record form (e-CRF) created using on line portal (google e-forms) wherein details of patients treated within the 6 month period will be captured. Google e-CRF will be available to all participating centres free of charge and has ease of access for filling details on both computer, tablets or mobile phone platforms. The e-form is user friendly and provides automated excel output and basic trends of responses and is ideal to be used across busy departments and low resource settings. To maintain data security, no patient identifying information will be collected. Each institution will be provided an institution id and name identifiers will not be used. Similarly a code will be generated for each of the patient and details of that code will remain with the parent institution.

Interventions

OTHERNot applicable- observational study

Compliance to Cervical Cancer Chemoradiation treatment guidelines

Sponsors

Tata Memorial Hospital
Lead SponsorOTHER_GOV
Post Graduate Institute of Medical Education and Research, Chandigarh
CollaboratorOTHER
MNJ Institute of Oncology and Regional Cancer Center
CollaboratorOTHER_GOV
Christian Medical College, Vellore, India
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned. Furthermore any cases referred to the institution for brachytherapy alone will also be included.

Design outcomes

Primary

MeasureTime frameDescription
report on institutional compliance to National Cancer Grid cervical cancer guidelines for chemo-radiation.3 MonthsTo report praportion of patients with No deviation, Major \& Minor Deviation and unacceptable deviation for chemoradiation guidlines.

Secondary

MeasureTime frame
To compute relative risk of suboptimal treatment for cervical cancer in reference to infrastructural and manpower deficits3 years
To report on factors impacting compliance to standard guidelines3years
To report adequacy of infrastructural and manpower requirements for optimal treatment of cervical cancer in NCG centres and corresponding state of origin3 years

Countries

India

Contacts

CONTACTDr. Supriya Chopra, MD
supriyasastri@gmail.com9930958309
PRINCIPAL_INVESTIGATORDr. Supriya Chopra, MD

ACTREC, Tata Memorial Centre, Navi Mumbai India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026